Top Growth Companies With Strong Insider Ownership September 2026
Over the last 7 days, the United States market has experienced a slight decline of 1.6%, yet it has shown resilience with a 12% rise over the past year and anticipated earnings growth of 17% per annum in the coming years. In this context, identifying growth companies with strong insider ownership can be crucial as they often indicate confidence from those who know the business best, potentially aligning their interests with those of external investors.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Uxin (UXIN) | 34.3% | 69.4% |
| Upstart Holdings (UPST) | 14.2% | 68.4% |
| Standard Nuclear (STDN) | 18.8% | 61.3% |
| Precigen (PGEN) | 11.7% | 55.4% |
| Nu Holdings (NU) | 22.8% | 21.8% |
| Karman Holdings (KRMN) | 14.4% | 56.2% |
| Himax Technologies (HIMX) | 29.2% | 70.2% |
| Dave (DAVE) | 16.9% | 23.6% |
| Carlyle Group (CG) | 27.4% | 22% |
| Almonty Industries (ALM) | 10.8% | 38% |
Here we highlight a subset of our preferred stocks from the screener.
Astrana Health (ASTH)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Astrana Health, Inc. is a healthcare management company that offers medical care services in the United States with a market cap of $2.03 billion.
Operations: The company's revenue is primarily derived from three segments: Care Delivery at $338.73 million, Care Partners at $3.63 billion, and Care Enablement at $339.54 million.
Insider Ownership: 10.7%
Earnings Growth Forecast: 29.0% p.a.
Astrana Health demonstrates potential as a growth company with high insider ownership, despite its revenue growth forecast of 8.4% per year lagging behind the US market. The company's earnings are expected to grow significantly at 29% annually, outpacing the broader market. Recent strategic moves include seeking acquisitions to enhance Care Delivery capabilities, and leadership changes aimed at accelerating growth and operational expansion. Despite trading below fair value estimates, interest payments remain a concern for financial stability.
- Click here to discover the nuances of Astrana Health with our detailed analytical future growth report.
- According our valuation report, there's an indication that Astrana Health's share price might be on the cheaper side.
Tempus AI (TEM)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Tempus AI, Inc. is a healthcare technology company based in the United States with a market cap of $11.22 billion.
Operations: The company generates revenue from its Medical Labs & Research segment, which amounts to $1.43 billion.
Insider Ownership: 34.9%
Earnings Growth Forecast: 43.6% p.a.
Tempus AI is expanding its genomic research capabilities with a large-scale whole-genome sequencing initiative, aiming to enhance AI-driven insights in disease research. Recent FDA clearance for its ECG-PH software adds to its cardiovascular portfolio. Despite high revenue growth forecasts of 17.5% annually, insider selling has been significant recently, and the share price remains volatile. Tempus plans to achieve profitability within three years while leveraging strategic collaborations to bolster its oncology diagnostics offerings.
- Dive into the specifics of Tempus AI here with our thorough growth forecast report.
- The analysis detailed in our Tempus AI valuation report hints at an inflated share price compared to its estimated value.
Zeta Global Holdings (ZETA)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Zeta Global Holdings Corp. operates an omnichannel data-driven cloud platform offering consumer intelligence and marketing automation software to enterprises globally, with a market cap of approximately $7.78 billion.
Operations: The company's revenue is primarily derived from its Internet Software & Services segment, which generated approximately $1.57 billion.
Insider Ownership: 11.4%
Earnings Growth Forecast: 49.1% p.a.
Zeta Global Holdings is poised for revenue growth of 13.9% annually, outpacing the US market's average. The company is trading at a significant discount to its estimated fair value, and earnings are expected to grow by 49.05% per year as it becomes profitable within three years. Recent strategic moves include a $25 million equity offering and partnerships with Palantir Technologies to enhance AI capabilities, alongside leadership changes aimed at strengthening marketing and communications strategies.
- Click here and access our complete growth analysis report to understand the dynamics of Zeta Global Holdings.
- Upon reviewing our latest valuation report, Zeta Global Holdings' share price might be too pessimistic.
Key Takeaways
- Navigate through the entire inventory of 183 Fast Growing US Companies With High Insider Ownership here.
- Seeking Other Investments? Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com